IRVINE, Calif., Aug. 27, 2007 (PRIME NEWSWIRE) -- An updated research report focusing on NeoStem, Inc. (AMEX:NBS) has been published for the benefit of interested investors. Any investors seeking guidance in the stem cell arena are encouraged to explore this company and its industry.
"With capital and key personnel in place, NBS may now focus on marketing, sales and business development -- driving business through the existing collection agreements, and building the collection infrastructure," stated the Murphy Analytics Report, written by Patrick Murphy, C.F.A. "With the capital to implement a multi-faceted, direct-to-consumer marketing campaign, NBS customer acquisition should begin in earnest over the next few quarters, driven initially by existing collection agreements."
The full report is available free of charge to all interested investors at http://www.trilogy-capital.com/tcp/neostem/. NeoStem has engaged Murphy Analytics to provide research coverage under the compensation terms described in the report.
An informational report focusing on NeoStem, Inc. and stem cell related companies has been published by financial courier StockUpTicks.com and is available free of charge to the general public.
The informational report will address preeminent and emerging stem cell companies such as Aastrom Biosciences Inc. (Nasdaq:ASTM), Geron Corp. (Nasdaq:GERN), ViaCell (Nasdaq:VIAC) and NeoStem.
The profile is available at the following link:
http://stockupticks.com/profiles/8-19-07.html
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.
The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells -- providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.
For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen thousand dollars by Trilogy Capital, an investor relations advisor to NeoStem, Inc, for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.